OverviewSuggest Edit

Mersana Therapeutics is a clinical-stage biotechnology company with highly differentiated and proprietary antibody drug conjugate, or ADC, platforms that allow for significantly higher drug loads, with the potential to provide greater efficacy while simultaneously increasing tolerability. It engineers immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. Because the Company can safely deliver higher quantities of therapeutic payloads directly to a tumor, Mersana’s ADC therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.

TypePublic
Founded2005
HQCambridge, US
Websitemersana.com
Employee Ratings4.8

Latest Updates

Employees (est.) (Jan 2019)86(+11%)
Revenue (FY, 2016)$25.2 M(+143%)
Share Price (Sept 2020)$24.2 (+30%)
Cybersecurity ratingAMore

Key People/Management at Mersana Therapeutics

David Mott

David Mott

Chairman
Lawrence Alleva

Lawrence Alleva

Director
Brian C. Deschuytner

Brian C. Deschuytner

Senior Vice President of Finance and Product Strategy
Kristen M. Hege

Kristen M. Hege

Director
Anna Protopapas

Anna Protopapas

President and Chief Executive Officer, Director
Dirk Huebner

Dirk Huebner

Chief Medical Officer
Show more

Mersana Therapeutics Office Locations

Mersana Therapeutics has an office in Cambridge
Cambridge, US (HQ)
840 Memorial Dr
Show all (1)

Mersana Therapeutics Financials and Metrics

Mersana Therapeutics Revenue

Mersana Therapeutics's revenue was reported to be $25.17 m in FY, 2016 which is a 143% increase from the previous period.
USD

Revenue (FY, 2016)

25.2m

Revenue growth (FY, 2015 - FY, 2016), %

143%

Net income (FY, 2016)

(13.7m)

Market capitalization (14-Sept-2020)

1.7b

Closing stock price (14-Sept-2020)

24.2

Cash (31-Dec-2016)

100.3m
Mersana Therapeutics's current market capitalization is $1.7 b.
USDFY, 2015FY, 2016

Revenue

10.4m25.2m

Revenue growth, %

143%

General and administrative expense

5.3m7.0m

R&D expense

21.4m32.0m
USDFY, 2015FY, 2016

Cash

11.5m100.3m

Accounts Receivable

640.0k1.1m

Current Assets

12.8m102.2m

PP&E

1.3m2.5m
USDFY, 2015FY, 2016

Net Income

(16.4m)(13.7m)

Depreciation and Amortization

297.0k655.0k

Accounts Payable

926.0k(325.0k)

Cash From Operating Activities

(9.6m)31.6m
USDFY, 2015

Financial Leverage

-0.3 x
Show all financial metrics

Mersana Therapeutics Operating Metrics

Apr, 2017

Patents (US)

7

Patents Pending (US)

10
Show all operating metrics

Mersana Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Mersana Therapeutics Online and Social Media Presence

Embed Graph

Mersana Therapeutics News and Updates

Thinking about buying stock in Cassava Sciences, Mersana Therapeutics, Sorrento Therapeutics, Dynavax Technologies, or Co-Diagnostics?

NEW YORK, Sept. 14, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SAVA, MRSN, SRNE, DVAX, and CODX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding...

Mersana Therapeutics Announces Second Quarter 2020 Financial Results and Provides Business Update

 - Presented positive interim expansion cohort data from XMT-1536 Phase 1 study at ASCO demonstrating a 35% objective response rate, including 10% complete response rate and 80% disease control rate in ovarian cancer

Mersana Therapeutics Reports Positive Interim Data from the Expansion Portion of the XMT-1536 Phase 1 Study

- Achieved 35% objective response rate, including 10% complete response rate, and 80% disease control rate among twenty evaluable patients with ovarian cancer

Mersana Therapeutics Raises $65 Million in Gross Proceeds Through its At-the-Market Facility

CAMBRIDGE, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that…

Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2019 Financial Results and Business Updates

CAMBRIDGE, Mass., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that i…

Mersana Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business Updates

XMT-1536 Expansion Study Continues According to Plan
Show more

Mersana Therapeutics Blogs

Mersana Therapeutics to Present at Jefferies Virtual Global Healthcare Conference

CAMBRIDGE, Mass. , May 28, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that

Mersana Therapeutics to Present Two Posters at the American Association for Cancer Research 2020 Virtual Annual Meeting

CAMBRIDGE, Mass. , May 15, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it

Mersana Therapeutics Announces Initiation of XMT-1592 Phase 1 Dose Escalation Study

CAMBRIDGE, Mass. , May 14, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the

Mersana Therapeutics to Present Interim Data from Phase 1 Expansion of XMT-1536 at the American Society of Clinical Oncology 2020 Virtual Scientific Program

Mersana Therapeutics to Present Interim Data from Phase 1 Expansion of XMT-1536 at the American Society of Clinical Oncology 2020 Virtual Scientific Program Content Import Wed, 05/13/2020 - 17:00 Mersana Therapeutics to Present Interim Data from Phase 1 Expansion of XMT-1536 at the America…

Mersana Therapeutics to Report Interim Data from Phase 1 Dose Expansion of XMT-1536

Mersana Therapeutics to Report Interim Data from Phase 1 Dose Expansion of XMT-1536 Content Import Wed, 05/13/2020 - 08:02 Mersana Therapeutics to Report Interim Data from Phase 1 Dose Expansion of XMT-1536 May 13, 2020 This release is a backfill from a News …

Mersana Therapeutics Announces First Quarter 2020 Financial Results and Provides Business Update

Recently presented promising XMT-1536 Phase 1 dose escalation data and established maximum tolerated dose, subsequently raising $65M of gross proceeds from the Company’s ATM facility Company to present interim data from the ongoing XMT-1536 Phase 1 dose expansion on a conference call on May 27,
Show more

Mersana Therapeutics Frequently Asked Questions

  • When was Mersana Therapeutics founded?

    Mersana Therapeutics was founded in 2005.

  • Who are Mersana Therapeutics key executives?

    Mersana Therapeutics's key executives are David Mott, Lawrence Alleva and Brian C. Deschuytner.

  • How many employees does Mersana Therapeutics have?

    Mersana Therapeutics has 86 employees.

  • What is Mersana Therapeutics revenue?

    Latest Mersana Therapeutics annual revenue is $25.2 m.

  • What is Mersana Therapeutics revenue per employee?

    Latest Mersana Therapeutics revenue per employee is $292.7 k.

  • Who are Mersana Therapeutics competitors?

    Competitors of Mersana Therapeutics include Araris Biotech, Grupo Biotoscana and Vertice Pharma.

  • Where is Mersana Therapeutics headquarters?

    Mersana Therapeutics headquarters is located at 840 Memorial Dr, Cambridge.

  • Where are Mersana Therapeutics offices?

    Mersana Therapeutics has an office in Cambridge.

  • How many offices does Mersana Therapeutics have?

    Mersana Therapeutics has 1 office.